ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
A plasma miRNA signature, including miR-495, as early diagnostic biomarkers associated with cognitive decline in Alzheimer's disease.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Peripheral and Central miRNA Signatures in Alzheimer's Disease: Tissue-Specific Variability, Sex-Associated Differences, and Implications for Blood-Based Biomarkers.International journal of molecular sciences · 2026Review
- Plasma multi-miRNA models classify Alzheimer's, Parkinson's, and Lewy body dementia.Frontiers in aging neuroscience · 2026Article
- A plasma miRNA signature, including miR-495, as early diagnostic biomarkers associated with cognitive decline in Alzheimer's disease.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionA definitive diagnosis of Alzheimer's disease (AD) requires the identification of pathological changes. Plasma miRNAs have emerged as potential AD diagnostic biomarkers.
methodsA matched case-control study was conducted using convenience sampling to evaluate the ability of candidate miRNAs in differentiating probable AD patients with mild cognitive impairment (MCI) or mild dementia (MD) stages. The initial sample included 29 patients and 58 controls. Plasma levels of miRNAs were measured by real-time polymerase chain reaction (RT-PCR) and their associations with scores from a comprehensive neuropsychological battery of cognitive tests analyzed by Spearman's correlation.
resultsA miR-181a, miR-181c, and miR-495 signature showed area-under-curve values indicative of strong diagnostic capacity and biomarker-based staging. Higher levels of these miRNAs were associated with worse scores in the different assessed cognitive tests. DISCUSSION: This study reports for the first-time alterations in plasma miR-495 levels in both MCI and MD patients. Future studies with larger cohorts are essential to validate the findings. Highlights: Alterations in plasma miR-495 levels are reported for the first time in AD patients.miR-181a, miR-181c, and miR-495 levels were higher in AD patients compared to controls.Higher levels of these miRNAs were related to worse cognitive test scores.miRNA signature was able to distinguish AD stages.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.